GSK plc announced that the European Commission has authorized Arexvy respiratory syncytial virus vaccine, recombinant adjuvanted for active immunization for the prevention of lower respiratory tract disease caused by respiratory syncytial virus, or RSV, in adults aged 50-59 who are at increased risk. Since June 2023, GSK‘s RSV vaccine has been approved in Europe for adults aged 60 and over for the prevention of RSV-LRTD, the company noted.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GSK:
- GSK says Delaware Supreme Court to review Superior Court Daubert decision
- GSK Pharma call volume above normal and directionally bullish
- GSK Pharma put volume heavy and directionally bearish
- GSK receives U.S. FDA Breakthrough Therapy Design for GSK5764227
- GSK Wins Latest Zantac Lawsuit Over Cancer Claims